<DOC>
	<DOCNO>NCT00600860</DOCNO>
	<brief_summary>Study Objectives : To collect describe demographic , disease-management , treatment outcome Myelodysplastic Syndromes ( MDS ) patient newly diagnose classify accord WHO criterion . To perform observational study concern relevant scientific research question MDS use clinical data biological sample , present relevant research outcomes field diagnosis prognostication , health relate quality life issue , health economics , risk stratification newly develop class drug . To disseminate result study stakeholder involve .</brief_summary>
	<brief_title>A Prospective , Multicentre European Registry Newly Diagnosed Patients With Myelodysplastic Syndromes</brief_title>
	<detailed_description>Methodology : Data patient MDS collect prospectively diagnosis 6-months interval diagnosis . The data gather seventeen ( ) country represent within LeukemiaNet MDS Working Party combine one central European Database . Data analysis conduct Data Management Centre University York various sub study , every 500 patient include European Registry end follow-up period . Number Patients &amp; Centres Over 140 hematology centre seventeen ( ) different country ( Austria , Croatia , Czech Republic , Denmark , France , Germany , Greece , Israel , Italy , The Netherlands , Romania , Spain , Sweden United Kingdom ) participate referral centre Registry . The recruitment target minimum 3000 case lower-risk MDS 1000 higher-risk case . Population : The study population consist newly diagnose patient subtypes MDS classify accord WHO criterion , include therapy-related MDS MDS-F , AML 20-30 percent marrow blast ( former RAEB-t ) , CMML form mixed MDS/MPD . Study Duration : The enrolment time schedule continue least June 2020 extension recruitment period possible . Patients follow withdrawal ( reason ) termination EUMDS Registry .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<criteria>Patients must meet follow criterion Age &gt; 18 year Newly diagnose patient ( within 100 day date diagnostic BM aspirate ) MDS classify accord current WHO criteria All sub group MDS Therapyrelated MDS MDS Fibrosis ( MDSF ) AML 2030 percent marrow blast ( former RAEBt ) CMML form mixed MDS/MPD IPSS IPSSR Risk group classification ( mandatory ) Able willing provide write informed consent Age &lt; 18 year Patient unwilling unable give consent AML â‰¥30 percent marrow blast accord WHO Patients inv ( 16 ) , ( 5 ; 17 ) ( 8 ; 21 ) consider AML therefore eligible Patients high risk MDS progress previously diagnose low risk MDS register within 100 day first diagnosis ( low risk ) MDS</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>MDS ( IPSS subtypes )</keyword>
	<keyword>Newly diagnose</keyword>
</DOC>